References
- Bazzano AN, Martin J, Hicks E, Faughnan M, Murphy L. Human-centred design in global health: A scoping review of applications and contexts. PLoS One. 2017;12(11):e0186744. doi:10.1371/journal.pone.0186744. PMID:29091935.
- Hoppe C, Obermeier P, Muehlhans S, Alchikh M, Seeber L, Tief F, Karsch K, Chen X, Boettcher S, Diedrich S, Conrad T, Kisler B, Rath B. Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study. Drug Saf. 2016;39(10):977–88. doi:10.1007/s40264-016-0437-6. PMID:27350063.
- Karsch K, Chen X, Miera O, Peters B, Obermeier P, Francis RC, Amann V, Duwe S, Fraaij P, Heider A, de Zwart M, Berger F, Osterhaus A, Schweiger B, Rath B. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Eur J Drug Metab Pharmacokinet. 2016;42(1):155–64. doi:10.1007/s13318-016-0330-9.
- Maurer W, Seeber L, Rundblad G, Kochhar S, Trusko B, Kisler B, Kush R, Rath B. Standardization and simplification of vaccination records. Expert Rev Vaccines. 2014;13(4):545–559. doi:10.1586/14760584.2014.892833. PMID:24597495.
- Obermeier P, Muehlhans S, Hoppe C, Karsch K, Tief F, Seeber L, Chen X, Conrad T, Boettcher S, Diedrich S, Rath B. Enabling Precision Medicine With Digital Case Classification at the Point-of-Care. EBioMedicine. 2016;4:191–6. doi:10.1016/j.ebiom.2016.01.008. PMID:26981582.
- Rath B. The ViVI Disease Severity Score. Duke Margolis Center/ FDA Workshop: ‘Advancing Drug Development for Respiratory Syncytial Virus’. Washington, DC, USA: Duke Margolis Center; 2016.
- Rath B, Conrad T, Karsch K, Tief F, Obermeier P, Chen X, Seeber L, Adamou E, Reiche J, Schweiger B. A Standardized Clinical Outcome Parameter for Infants and Children with Influenza-like Illness (ILI). 3rd ISIRV Antiviral Group Conference, ‘Influenza and Other Respiratory Virus Infections: Advances in Clinical Management’; 2014; Tokyo, Japan.
- Rath B, Conrad T, Myles P, Alchikh M, Ma X, Hoppe C, Obermeier P, Kisler B, Schweiger B. Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. Expert Review of Anti-infective Therapy. 2017;15(6):545–68. doi:10.1080/14787210.2017.1295847. PMID:28277820.
- Rath B, Maltezou HC, Papaevangelou V, Papagrigoriou-Theorodridou MA, Alchikh M, Myles P, Schweiger B, Network tP. Partnering for Enhanced Digital Surveillance of Influenza-like Disease and the Effect of Antivirals and Vaccines (PEDSIDEA). 2017; Submitted in peer review.
- Seeber L, Conrad T, Hoppe C, Obermeier P, Chen X, Karsch K, Muehlhans S, Tief F, Boettcher S, Diedrich S, Schweiger B, Rath B. Educating parents about the vaccination status of their children: A user-centered mobile application. Prev Med Rep. 2017;5:241–50. doi:10.1016/j.pmedr.2017.01.002. PMID:28127527.
- Seeber L, Michl B, Rundblad G, Trusko B, Schnjakin M, Meinel C, Weinberg U, Gaedicke G, Rath B. A design thinking approach to effective vaccine safety communication. Curr Drug Saf. 2015;10(1):31–40. doi:10.2174/157488631001150407105400. PMID:25859673.
- Tief F, Hoppe C, Seeber L, Obermeier P, Chen X, Karsch K, Muhlhans S, Adamou E, Conrad T, Beresniak A, Schweiger B, Adam T, Rath B. An inception cohort study assessing the role of pneumococcal and other bacterial pathogens in children with influenza and ILI and a clinical decision model for stringent antibiotic use. Antivir Ther. 2016;21(5):413–24. doi:10.3851/IMP3034. PMID:26867096.
- Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses. 2016;10(1):2–8.